Latest news with #FISH
Business Wire
2 days ago
- Business
- Business Wire
ALIKO SCIENTIFIC (Ikonisys SA), Through Its Fully Owned Italian Subsidiary Hospitex International, Signs Exclusive Distribution Agreement for Italy with Menarini Diagnostics
FLORENCE, Italy & PARIS--(BUSINESS WIRE)--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) Euronext Growth: ALIKO, through its fully owned Italian subsidiary Hospitex International is pleased to announce the signing of an exclusive distribution agreement with Menarini Diagnostics, the European largest distributor in the field of pathology and IVD (in vitro diagnostics). Under the terms of the agreement, Menarini Diagnostics will exclusively distribute, in the Italian market, ALIKO SCIENTIFIC group's product portfolio that includes FISH technology (manufactured in the USA by Ikonisys) and Hospitex's full range of cytology, cell-blocking and rapid immunohistochemistry products. Menarini Diagnostics Italy, part of Menarini pharmaceutical group, is the European largest IVD distribution player, with a track record and extensive experience in pathology. The company already distributes products from leading global manufacturers in the sector. The addition of the ALIKO SCIENTIFIC business lines will further enhance Menarini's offering, complementing its current histology solutions for anatomical pathology laboratories and thus achieving one of the most comprehensive and integrated offers in the market. Hospitex has estimated the addressable Italian market for cytology and cell block product lines at approximately €28 million annually. Market forecasts for the FISH and immunohistochemistry segments will be developed following market entry and the collection of relevant data. The Group's goal is to capture a significant share of the market within the first three years of commercial rollout. Francesco Trisolini, CEO of Hospitex, commented: "This agreement with Menarini Diagnostics represents a major milestone for the Group. By partnering with the largest European IVD distributor, we are confident that our innovative solutions will reach a broader market and significantly improve diagnostic capabilities in pathological anatomy. This agreement will also fuel our R&D programs to release new breakthrough solutions for the cancer diagnostics market, such as FISH probes in a short timeframe." Fabio Piazzalunga, Global Head of Diagnostics and General Manager of Menarini Diagnostics, added: "At Menarini, we are deeply committed to advancing oncology diagnostics, and the addition of ALIKO SCIENTIFIC's cutting-edge technology to our portfolio aligns perfectly with our strategic vision. This collaboration will allow us to offer a more comprehensive suite of solutions to pathology professionals across Italy." About ALIKO SCIENTIFIC (Ikonisys SA) Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology. For more information, visit: About IKONISYS Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes. For more information, visit: About HOSPITEX Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics. For more information, visit: Disclaimer This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.
Yahoo
2 days ago
- Business
- Yahoo
ALIKO SCIENTIFIC (Ikonisys SA), Through Its Fully Owned Italian Subsidiary Hospitex International, Signs Exclusive Distribution Agreement for Italy with Menarini Diagnostics
FLORENCE, Italy & PARIS, June 04, 2025--(BUSINESS WIRE)--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) Euronext Growth: ALIKO, through its fully owned Italian subsidiary Hospitex International is pleased to announce the signing of an exclusive distribution agreement with Menarini Diagnostics, the European largest distributor in the field of pathology and IVD (in vitro diagnostics). Under the terms of the agreement, Menarini Diagnostics will exclusively distribute, in the Italian market, ALIKO SCIENTIFIC group's product portfolio that includes FISH technology (manufactured in the USA by Ikonisys) and Hospitex's full range of cytology, cell-blocking and rapid immunohistochemistry products. Menarini Diagnostics Italy, part of Menarini pharmaceutical group, is the European largest IVD distribution player, with a track record and extensive experience in pathology. The company already distributes products from leading global manufacturers in the sector. The addition of the ALIKO SCIENTIFIC business lines will further enhance Menarini's offering, complementing its current histology solutions for anatomical pathology laboratories and thus achieving one of the most comprehensive and integrated offers in the market. Hospitex has estimated the addressable Italian market for cytology and cell block product lines at approximately €28 million annually. Market forecasts for the FISH and immunohistochemistry segments will be developed following market entry and the collection of relevant data. The Group's goal is to capture a significant share of the market within the first three years of commercial rollout. Francesco Trisolini, CEO of Hospitex, commented: "This agreement with Menarini Diagnostics represents a major milestone for the Group. By partnering with the largest European IVD distributor, we are confident that our innovative solutions will reach a broader market and significantly improve diagnostic capabilities in pathological anatomy. This agreement will also fuel our R&D programs to release new breakthrough solutions for the cancer diagnostics market, such as FISH probes in a short timeframe." Fabio Piazzalunga, Global Head of Diagnostics and General Manager of Menarini Diagnostics, added: "At Menarini, we are deeply committed to advancing oncology diagnostics, and the addition of ALIKO SCIENTIFIC's cutting-edge technology to our portfolio aligns perfectly with our strategic vision. This collaboration will allow us to offer a more comprehensive suite of solutions to pathology professionals across Italy." About ALIKO SCIENTIFIC (Ikonisys SA) Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC's mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic investments to create a global center of excellence in oncology. For more information, visit: About IKONISYS Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes. For more information, visit: About HOSPITEX Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest standards of quality. Hospitex offers the world's most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics. For more information, visit: Disclaimer This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results. View source version on Contacts Ikonisys Alessandro MauriCFOinvestors@ NewCap Louis-Victor Delouvrier/Aurélie ManavarereInvestor Relationsikonisys@ Tel.: +33 (0)1 44 71 94 94 NewCap Arthur RouilléMedia Relationsikonisys@ Tel.: +33 (0)1 44 71 00 15
Yahoo
23-05-2025
- General
- Yahoo
Over $175k awarded to environmental education projects in Central Pennsylvania
PENNSYLVANIA (WTAJ) — The Pennsylvania Department of Environmental Protection (DEP) awarded over $1 million for projects across the state that work to promote environmental stewardship, including several in Central Pennsylvania. The funding comes from the Environmental Education Grants program, which works to educate those who live or work in areas that are affected by climate change, air pollution, and water pollution. According to the DEP, 87% of projects that received funding will work to captivate youth and adults on those topics. $200,000 in scholarships awarded to Somerset seniors Here are local projects: Huntingdon County Pennsylvania State University was awarded $30,000 for the 'Penn State K-12 Sustainability Summit 2025.' The project will host 50 education leaders from 22 school districts to help increase sustainability efforts in the K-12 space. Blair and Huntingdon County Blair County Conservation District was awarded $30,000 for 'Regional Education on Healthy Soils, Riparian Buffers and Urban Green Spaces.' Interactive Stormwater Management programs and learning stations will be delivered to students, families and community members Somerset County Mountain Watershed Association was awarded $30,000 to conduct 'Expanding Outdoor Education in the Youghiogheny River Watershed' in multiple counties, including Somerset. The project will provide immersive hands-on programs, free community workshops, organized nature walks, fishing clinics, and service-learning opportunities. Centre County Pennsylvania State University was awarded $28,100 to deliver 'Equipping Educators through First Investigation of Stream Health Protocol Workshops.' Educators from multiple counties, including Centre County, will learn the First Investigation of Stream Health (FISH) protocol and be provided supplies to guide middle and high school youth investigations. Jefferson County Pennsylvania State University was awarded $30,000 to deliver a 'Per-and Poly-Fluorinated Alkyl Substances (PFAS) workshop for Extension Educators and Volunteers.' Participants from multiple counties, including Jefferson County, will learn about PFAs fundamentals and management and, in turn, deliver community education programs. Cambria and Somerset County The Watersmith Guild, Inc. was awarded $27,188 to provide 18 'First Waves' workshops in counties, including Cambria and Somerset counties. Youth will engage in river and stewardship experiences and create digital media documentary films about their adventures. 'These projects help connect people to the ways we can protect the air we breathe and the water we drink, and many of them encourage learning at any age, whether you're a kid or an adult,' DEP Acting Secretary Jessica Shirley said. 'Every grant we are awarding supports educational opportunities and will further improve people's connections to their environment.' You can read the full list of the 68 projects that received funding on the DEP website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
21-04-2025
- Sport
- Yahoo
Dodgers on Deck: Tuesday at Nationals
NATHAN J. FISH/THE OKLAHOMAN / USA TODAY NETWORK via Imagn Images The Dodgers continue their series against the Nationals on Tuesday night at Nationals Park in Washington D.C., and will have a new starting pitcher on the mound. Tuesday was the scheduled day for Blake Snell to start, but the left-hander was placed on the injured list on Sunday with shoulder inflammation. In his place, the team will call up Justin Wrobleski to start on Tuesday, manager Dave Roberts told reporters on Monday in Washington. Advertisement Wrobleski last pitched last Wednesday with Triple-A Oklahoma City, tossing 5⅔ scoreless innings with three strikeouts against El Paso. He'll be on five days rest on Tuesday. Tuesday game info Teams: Dodgers at Nationals Stadium: Nationals Park, Washington D.C. Start time: 3:45 p.m. PT TV: SportsNet LA Radio: AM 570 (English), KTNQ 1020 AM (Spanish) More from
